Your shopping cart is currently empty

ROC-325 is an effective and orally active inhibitor of autophagy with anticancer activity. ROC-325 induces renal cell carcinoma apoptosis and exhibits favorable selectivity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $47 | In Stock | In Stock | |
| 10 mg | $78 | In Stock | In Stock | |
| 25 mg | $165 | In Stock | In Stock | |
| 50 mg | $265 | In Stock | In Stock | |
| 100 mg | $413 | In Stock | In Stock | |
| 200 mg | $589 | - | In Stock |
| Description | ROC-325 is an effective and orally active inhibitor of autophagy with anticancer activity. ROC-325 induces renal cell carcinoma apoptosis and exhibits favorable selectivity. |
| In vitro | ROC-325 (5 μM) leads to the formation of LC3B punctae and a robust increase in LC3B levels in both A498 and 786-0 RCC cells. ROC-325 promotes a dose-dependent increase in LC3B expression in a manner that correlated with a corresponding increase in the levels of p62 and cathepsin D. ROC-325 inhibits cells growth with IC50 values of 4.9 μM, 11 μM, 4.6 μM, 5.4 μM, 7.4 μM, 11 μM, 8.2 μM, 5.8 μM, 5.0 μM, 11 μM, 8.4 μM and 6.0 μM for A498, A549, CFPAC-1, COLO-205, DLD-1, IGROV-1, MCF-7, MiaPaCa-2, NCI-H69, PC-3, RL and UACC-62 cells, respectively. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux[1]. |
| In vivo | In mice bearing 786-0 RCC xenografts, ROC-325 (25, 40, and 50 mg/kg; oral) leads to significant, dose-dependent inhibition of disease progression and inhibits autophagy in vivo[1]. |
| Molecular Weight | 503.06 |
| Formula | C28H27ClN4OS |
| Cas No. | 1859141-26-6 |
| Smiles | CN(CCNc1ccnc2cc(Cl)ccc12)CCNc1ccc(C)c2sc3ccccc3c(=O)c12 |
| Relative Density. | 1.344 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: 1 mg/mL (1.99 mM), Sonication is recommended. H2O: 0.8 mg/mL (1.59 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
H2O/DMSO
| |||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.